+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy



Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy



Antimicrobial Agents and ChemoTherapy 48(12): 4574-4581



This study was conducted to evaluate risk factors for mortality and treatment outcome of bloodstream infections due to extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EK). ESBL production in stored K. pneumoniae and E. coli blood isolates from Jan 1998 to Dec 2002 was phenotypically determined according to NCCLS guidelines and/or the double-disk synergy test.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011813768

Download citation: RISBibTeXText

PMID: 15561828

DOI: 10.1128/aac.48.12.4574-4581.2004


Related references

Bloodstream infections due to extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae Risk factors for mortality and clinical outcome, with special emphasis on antimicrobial therapy. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 364, 2003

Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Revista do Instituto de Medicina Tropical de Sao Paulo 51(4): 211-216, 2009

Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 365, 2003

Risk Factors for Ciprofloxacin Resistance in Bloodstream Infections Due to Extended-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. Microbial Drug Resistance 10(1): 71-76, 2004

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Medicine 28(12): 1718-1723, 2002

Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-beta-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli. 2012

Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scandinavian Journal of Infectious Diseases 45(7): 519-525, 2013

Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infection Control and Hospital Epidemiology 29(7): 671-674, 2008

Risk factors for bloodstream infections caused by extended-spectrum ?-lactamase-producing Escherichia coli and Klebsiella pneumoniae. The Brazilian Journal of Infectious Diseases 15(4): 370-376, 2011

Risk factors for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Brazilian Journal of Infectious Diseases 15(4): 370-376, 2012

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrobial Agents and ChemoTherapy 46(5): 1481-1491, 2002

Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Journal of Microbiology, Immunology, and Infection 50(3): 355-361, 2015

Bloodstream infections by extended spectrum beta-lactamase -producing Escherichia coli and Klebsiella pneumoniae in children Epidemiologic investigation and clinical outcome. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 420, 2001

Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrobial Agents and ChemoTherapy 56(7): 3936-3942, 2012

Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrobial Agents and ChemoTherapy 52(9): 3244-3252, 2008